Approval grants EU providers access to crucial
life-saving device, indicative of the company's global growth and
ability to increase emergency and trauma care
LONDON,
ON., April 23, 2024 /PRNewswire/ -- Front
Line Medical Technologies Inc, a leader in innovative medical
devices for emergency and trauma care, today announced that its
innovative COBRA-OS® (Control Of Bleeding, Resuscitation, Arterial
Occlusion System) has officially been granted CE marking under the
new European Medical Device Regulations.
EU medical providers now have full access to this unique 4
French aortic occlusion device, the first of its kind to be
approved through the new MDR system. Already with FDA clearance and
Health Canada approval, the COBRA-OS® CE marking highlights the
company's substantial market expansion, solidifying Front Line
Medical Technologies as a true industry player.
"The CE marking of the COBRA-OS® is momentous for our company,
as it reinforces our dedication to technological excellence and our
unwavering commitment to better patient care," said Dr.
Asha Parekh, CEO of Front Line
Medical Technologies. "Day in and day out, our pursuit of helping
to save as many lives as we can is what drives our entire team, and
this regulatory achievement means we are further on our way to
accomplishing that goal."
The COBRA-OS® is most notable for its ultra-low profile. It also
doesn't require an over-the-wire technique, which speeds up
deployment and buys valuable time until definitive care can be
provided and is conveniently accompanied by a 4 French mini-access
sheath kit and a 10 cc sword-handled syringe.
"The COBRA-OS® – from conception to fruition is built on Front
Line Medical Technologies' commitment to always putting the needs
of patients first," said Dr. Adam
Power, CMO of Front Line Medical Technologies. "CE marking
of the COBRA-OS® represents a significant advancement in the field,
prioritizing patient safety with a focus on reducing complications
and simplifying aortic occlusion."
"Entrance into the EU market as an avenue to increase medical
access to COBRA-OS® is a natural move for the company, considering
our mission of reaching more patients," said Seema Gogna, Director of Products of Front Line
Medical Technologies. "With the achievement of CE marking, we are
moving the needle in expanding access on a global scale, and we
will continue to take steps towards touching more lives and
improving outcomes."
About Front Line Medical Technologies Inc
Front Line Medical Technologies Inc. is a Canadian medical
device company driven by its commitment to lowering the barriers in
bleeding control and resuscitation worldwide. The company is the
innovator behind the COBRA-OS® (Control of Bleeding,
Resuscitation, Arterial Occlusion System), the smallest life-saving
REBOA (Resuscitative Endovascular Balloon Occlusion of the Aorta)
device currently available, with FDA clearance, Health Canada
approval and CE marking. Notable for its low-profile design, ease
of use and rapid and precise deployment, the COBRA-OS® provides
controlled occlusion of a patient's aorta in critical medical
situations when awaiting definitive care. To learn more, visit our
website, and follow us on LinkedIn, X, Facebook, YouTube and
Instagram.
Media Contact:
Chelsea Kershaw
(909) 573-7237
376626@email4pr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/front-line-medical-technologies-announces-ce-marking-for-cobra-os-smallest-aortic-occlusion-device-on-the-market-302124755.html
SOURCE Front Line Medical Technologies